How to store Orforglipron
A daily GLP-1 pill approved in the US for adult weight management.
Also called: LY3502970, LY-3502970, OWL833, Foundayo.
Oral GLP-1 agonists · Nonpeptide GLP-1 receptor agonist · Evidence: Approved drug.
Comes as: Approved film-coated oral tablets: 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg, Investigational oral capsules used different strengths.
Mixed with: None. Do not reconstitute tablets or oral powder for injection..
- Swallow tablets whole; do not break, crush or chew.
- No validated community vial sizes, water volumes or mixed-product stability were found.
Before mixing: Store at 20–25°C, briefly at 15–30°C. Each 30-tablet bottle includes a moisture absorber and child-resistant cap.
After mixing: No mixing or injectable preparation is specified for approved tablets.
Related to Orforglipron
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- FDA Approves First New Molecular Entity Under National Priority Voucher Program, FDA · 2026
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA · 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA · FDA · 2026
- Foundayo, European Medicines Agency · 2026
- Foundayo (orforglipron) tablets, FDA · 2026
- FOUNDAYO- orforglipron tablet, film coated, DailyMed · DailyMed · 2026
- The 2026 Monitoring Program, World Anti-Doping Agency · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- UK first in Europe to authorise orforglipron for weight management and type 2 diabetes, MHRA · 2026
- Weight Loss Drugs: What athletes need to know about GLP-1s, USADA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.